- After two candidate failures over the past two years, Cyclerion Therapeutics, Inc. is pinning its hopes on CNS therapy CY6463.
- The soluble guanylate cyclase modulator is currently undergoing mid-stage evaluation for one CNS indication and should enter a Phase 2 study for another in 2021.
- With a small market cap and no clinical data due until YE21, yet significant insider buying from the CEO, this busted IPO merited a deeper dive.
- A full investment analysis is provided in the paragraphs below.
For further details see:
Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021